Premium
[P2–230]: USING CSF MARKERS TO VALIDATE METABOLIC AND SYNAPTIC DYSFUNCTION HYPOTHESES OF ALZHEIMER's DISEASE (AD): META‐ANALYSIS
Author(s) -
Bass Brittany,
Scarpiello Sean,
Manyevitch Roni,
Protas Matthew,
Nanajian Anthony,
Chang Matthew,
Thompson Stefani,
Khoury Neil,
Deliso Marisa,
Perry George,
Trotz Margit,
Moore D Blaine,
Friederich Jan,
Nuguri Vivek,
Murray Ian V.J.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.882
Subject(s) - meta analysis , disease , biomarker , acetylcholine , medicine , neurotransmitter , glutamine , bioinformatics , neuroscience , biology , biochemistry , amino acid , central nervous system
panel of rat (APPsi) and mouse (Tg4-42) biofluids and tissues. This give further help to understand the devastating neurodegenerative disease, related complex biochemical pathways and pathophysiological processes of AD.Conclusions:UsingNMR-basedmetabolic phenotyping we defined a quantitative readout of transgenic animal models in the form of a biomarker panel. These biomarkers not only contribute to the understanding of this devastating neurodegenerative disease and the related pathophysiological processes on a systemic level, but set the base for a wide range of biomedical applications. Our approach can be easily extended to other tissues, matrices, or disease models and translated across species since metabolic pathways are conserved through evolution, and are essentially similar in rodents and humans.